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Background and purpose: Rectal toxicity presents a significant limiting factor in prostate radiotherapy regimens.
This study evaluated the safety and efficacy of an implantable and biodegradable balloon specifically designed to
protect rectal tissue during radiotherapy by increasing the prostate–rectum interspace.
Patients and methods: Balloons were transperineally implanted, under transrectal ultrasound guidance, into the
prostate–rectum interspace in 27 patients with localized prostate cancer scheduled to undergo radiotherapy.
Patients underwent two simulations for radiotherapy planning--the first simulation before implant, and the second
simulation seven days post implant. The balloon position, the dimensions of the prostate, and the distance
between the prostate and rectum were evaluated by CT/US examinations 1 week after the implant, weekly during
the radiotherapy period, and at 3 and 6 months post implant. Dose-volume histograms of pre and post
implantation were compared. Adverse events were recorded throughout the study period.
Results: Four of 27 patients were excluded from the evaluation. One was excluded due to a technical failure during
implant, and three patients were excluded because the balloon prematurely deflated. The balloon status was evaluated
for the duration of the radiotherapy period in 23 patients. With the balloon implant, the distance between the prostate
and rectum increased 10-fold, from a mean 0.22 ± 0.2 cm to 2.47 ± 0.47 cm. During the radiotherapy period the balloon
length changed from 4.25 ± 0.49 cm to 3.81 ± 0.84 cm and the balloon height from 1.86 ± 0.24 cm to 1.67 ± 0.22 cm. But
the prostate-rectum interspace distance remained constant from beginning to end of radiotherapy: 2.47 ± 0.47 cm and
2.41 ± 0.43 cm, respectively. A significant mean reduction in calculated rectal radiation exposure was achieved. The
implant procedure was well tolerated. The adverse events included mild pain at the perineal skin and in the anus. Three
patients experienced acute urinary retention which resolved in a few hours following conservative treatment. No
infections or thromboembolic events occurred during the implant procedure or during the radiotherapy period.
Conclusion: The transperineal implantation of the biodegradable balloon in patients scheduled to receive radiotherapy
was safe and achieved a significant and constant gap between the prostate and rectum. This separation resulted in
an important reduction in the rectal radiation dose. A prospective study to evaluate the acute and late rectal toxicity
is needed.
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Prospective randomized trials have demonstrated the ad-
vantage of dose-escalated radiotherapy in the treatment
of localized prostate cancer [1-3]. Despite the implemen-
tation of new radiotherapy technologies, such as inten-
sity modulated radiation therapy and image guided
radiation therapy, rectal toxicity has remained high, thus
limiting dose escalation [4-8]. Increased separation be-
tween the rectum and prostate gland is expected to re-
duce the rectal dose and improve both radiotherapy
safety and efficacy [9]. Two clinically relevant methods
have been tested to achieve this goal. The first involves
the injection of hyaluronic acid and human collagen to
create a space between the prostate and rectum. The ap-
proach with hyaluronic acid was tested and a significant
stable space between the prostate gland and the rectum
was achieved. Although the group of patients is small,
the results are promising and require further research
[10-12]. The second method involves the insertion of an
intra-rectal balloon to separate the rectum from the
prostate. With the exception of the anterior rectal wall, this
technique reduces the rectal dose, and achieves further
stabilization of the prostate. The intra-rectal balloon in
daily practice appears to achieve satisfactory results [13].
BioProtect Ltd, Israel has developed ProSpace™, a bio-
degradable balloon designed for transperineal implan-
tation between the prostate and rectum prior to external
beam prostate radiotherapy. The balloon has been shown
to remain inflated during the entire radiotherapy period,
and then later biodegrade without toxicity [14]. The bal-
loon’s safety and efficacy in separating the anterior rectal
wall from the surrounding tissue was established in a
mammalian model [15].
This prospective, international multi-center study evalu-
ated the safety of the implant procedure of a biodegrad-
able balloon (ProSpace™) and its efficacy in creating and
maintaining a significant space between the rectum and
prostate during the radiotherapy period.
Patients and methods
The study included 6 medical centers with different radi-
ation techniques and schedules (IMRT and 3-DCRT).
Because the aim of this study was the safety of the bal-
loon implant procedure and the ability to create a pre-
dictable and consistent space between the prostate and
rectum that was maintained during the entire period of
radiotherapy, the variations in treatment technique and
schedule were acceptable. This study was approved by
local institutional review boards and all patients partici-
pating in the study signed the approved informed con-
sent form (NIH registration number NCT00462124).
Patients: Patients with localized prostate cancer (T1-2,
N0, and M0) and 0–1 performance status scheduled for
prostate external beam radiotherapy were eligible forthis study. Normal blood counts, biochemistry, and clot-
ting test results, peak flow rate >13 ml/sec, and residual
urine volume below 150 mL were required at baseline.
Patients with a history of prior pelvic radiotherapy, pros-
tatectomy, cryosurgery or other surgical procedures in-
volving the prostate or peri-rectal and peri-prostatic
areas were excluded from the study. The implant proce-
dures were performed under general anesthesia; there-
fore patients with unstable angina pectoris, uncontrolled
congestive heart failure or recent myocardial infarction
were ineligible for enrollment in the study.
Methods: ProSpace™ contains an introducer and a
triangular-shaped balloon made of poly (L-Lactide-co-
caprolactone) which is a co-polymer of Poly Lactide acid
and epsilon Caprolactone, in a ratio of 70:30, a widely
used, medically biodegradable material. To enable inser-
tion, the balloon was folded into a cylindrical insertion
tube. The balloon was implanted in the Denonvilliers’
fascia, transperineally and guided by transrectal ultra-
sound (TRUS). After positioning the insertion tube spacer
between the prostate and the rectum, the balloon was in-
flated with sterile saline. The implant procedures were
performed with the patient under either general or local
anesthesia.
All patients underwent two CT-based simulations for
radiotherapy treatment planning--the first before the im-
plant, and a second CT simulation one week after im-
plant. Radiotherapy delivery was based on the second
simulation and treatment plan. The Clinical Target Volume
(CTV) was defined as the prostate gland and seminal vesi-
cles. The Planning Target Volume (PTV) included the
CTV with a 5 mm margin at the posterior border, and a
10 mm margin everywhere else. The external surface of
the entire urinary bladder, the entire rectum (from the
anal verge to the recto-sigmoid) and both hip joints were
contoured. The radiotherapy program was according to the
local policy. During weekly radiotherapy sessions, and at
follow-up visits 3 and 6 months post implantation, a cone-
beam CT or ultrasound examination was performed to
verify the position, geometry, and integrity of the balloon.
Dose-volume histograms (DVH) of pre and post implant
treatment plans were compared to evaluate the impact of
the balloon implant on the exposure of the rectum to radi-
ation. Although there is no consensus concerning the rec-
tal dose constraint, the V60 (volume receiving ≥60 Gy)
has consistently demonstrated an association with a risk
of Grade ≥2 rectal toxicity or rectal bleeding. Based on
this study and others, the following dosimetry criteria
were chosen for evaluation: V50, V60, D50, D70, D80,
D90 and D100 [16-19].
Target volumes were localized weekly with several
methods as a function of institutional preference (e.g., cone
beam CT, ultrasound). The device was particularly easy to
visualize with the CBCT technology. For the purpose of






Number of patients (%)
Number of patients evaluated: 26 23
Pain at the perineal skin
(1 & 7 VAS score):
7 (27) ———————
Acute pain in the anus
(2 & 9 VAS score):
4 (15) ———————
Acute urinary retention: 3 (12) 1 (4)
Dysuria and Nocturia (grade 1–2): 3(12) 15 (65)
Penile bleeding: 1 (4) ———————
Proctitis (Grade 1): ——————— 2 (8)
Diarrhea (Grade 1): ——————— 4 (17)
Signs of blood in feces (Grade 1): ——————— 1 (4)
Constipation (Grade 1): ——————— 1 (4)
Erectile dysfunction: ——————— 1 (4)
Pruritus: ——————— 1 (4)
Fatigue ——————— 1 (4)
Decreased urine flow: ——————— 1 (4)
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transferred to an independent imaging specialist who eval-
uated the following parameters: distance between prostate
and rectum, and the dimensions of the implantable balloon
and prostate gland. These parameters were measured and
analyzed before and after the implant procedure, weekly
during the radiotherapy period, and at 3 and 6 months
post-implant.
Adverse events (AE) observed or reported during bal-
loon implantation, throughout the radiotherapy period,
and for up to 6 months post implantation, were evalu-
ated according to the Common Terminology Criteria for
Adverse Events (CTCAE) Version 3.0 [20]. Pain was
scored using the visual analog scale (VAS).
Statistical analyses: Data were analyzed using SASW
V9.2 (SAS Institute, Cary NC, USA) and are presented
in tabular format. Continuous variables are summarized
by a mean ± standard deviation (or range) and categor-
ical variables by a count and percentage. The calculated
differences between pre-balloon and post-balloon rectal
dosimetry values were assessed using the Wilcoxon
Signed Rank test. A p-value ≤0.05 was considered statis-
tically significant.Results
Patients: From June 19, 2009 through November 23,
2010, 27 patients with localized prostate cancer from six
medical centers were enrolled in this study. The radiation
doses and the delivery techniques were in accordance with
local policies. Total radiation dose ranged from 70 Gy to
78 Gy with a daily fraction of 1.8, 2.0 and 2.5 Gy. Two of
the centers used conventional 3-dimensional conformal
radiation therapy and four centers utilized intensity modu-
lated radiation therapy (Table 1). Median time from im-










8 (30) 70.0 (2.5 X 28) IMRT
Lübeck University,
Germany
2 (7) 72.0 (2.0 X 36) 3DCRT
Padova Medical
Center, Italy
9 (33) 78.0 (2.0 X 39) 3DCRT
Massey Medical
Center, USA
1 (4) 78.0 (2.0 X 39) IMRT
Montefiore Medical
Center, USA
2 (7) 76.0 (1.8 X 42) IMRT
Virginia Urology,
Richmond, USA
5 (19) 75.6 (1.8 X 42) IMRT
78.0 (2.0 X 39)duration of radiotherapy was 39 days (range 28–45). 27
patients enrolled in the study and were evaluated for the
implant procedure. Of these, 23 were evaluated for safety
and efficacy of the balloon during the period of radiother-
apy. One patient was excluded from this analysis due to
an error in the implant procedure, and 3 other patients
were excluded due to premature balloon deflation which
is believed to be related to transrectal insertion of fiducial
markers into the prostate prior to the balloon implant.
Balloon implant procedure: The balloon implant pro-
cedure was successful in 26 of 27 patients. In one pa-
tient, balloon inflation failed due to a technical error. In
the remaining 26 patients, the transperineal implant pro-













26 23 23 23
Balloon in
place:
26 23 23 2
Balloon fully
inflated:
26 23 15 0
Balloon partly
inflated:
——— ——— 4 0
Balloon
deflated:
——— ——— 4 23
Table 4 Measurement of the prostate gland, balloon and prostate-rectum interspace
Pre implantation Post implantation End radiotherapy P value 3-month follow up P value
# of patients 26 26 18 18
Prostate measurements (cm)
Width 4.37 ± 0.59 4.39 ± 0.64 4.44 ± 0.86 4.15 ± 0.75
Length 3.74 ± 0.84 4.15 ± 1.08 4.29 ± 0.95 4.10 ± 1.27
Height 3.42 ± 0.79 3.17 ± 0.61 3.19 ± 0.69 3.14 ± 0.73
Balloon measurements (cm)
Width 3.06 ± 0.27 2.96 ± 0.25 NS 2.62 ± 0.58
Length 4.25 ± 0.49 3.81 ± 0.84 0.023 *1 2.97 ± 1.25 0.05 *3
Height 1.86 ± 0.24 1.67 ± 0.22 0.03 *2 1.28 ± 0.47 0.003*4
Prostate-rectum distance (cm)
0.22 ± 0.2 2.47 ± 0.47 2.41 ± 0.43 NS *5 1.59 ± 0.60 0.005*6
P values:
The change in length and height of the balloon between post implant and end of radiotherapy, *1 & *2, respectively.
The change in length and height of the balloon between end of radiotherapy and at 3 months, *3 & *4, respectively.
The change in the prostrate-rectum distance between post-implant and at the end of radiotherapy; and between the end of radiotherapy and at 3 months
post-implant,*5 & *6.
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thrombosis. The side effects included (Table 2): pain in the
perineal scar (range from 1–7, according to VAS), dysuria
grade 1 & 2 and one case of penile bleeding. Three pa-
tients developed acute urinary retention and required uri-
nary bladder catheterization which resolved within a few
hours. In the single patient for whom the implant failed,
the removal of the balloon was without complication.
During radiotherapy the most frequent side effect was
dysuria grade 1–2 (58%) and one patient developed acute
urinary retention and required urinary bladder cathe-
terization during the radiotherapy period. Two patients had
mild proctitis. Other side effects are presented in Table 2.
Balloon status (Table 3): The balloon status for the
duration of the radiotherapy period was evaluated in 23The implantable balloon
Figure 1 Axial view of CT scan, 7 days post balloon implant.of 26 patients. In all 23 patients, the balloon remained
inflated during the entire period of radiotherapy and did
not change its position in relation to the prostate gland.
At 3 months post implantation, balloon deflation was
observed in 8 patients (4 complete and 4 partially) and
by 6 months all balloons were completely deflated in all
patients. At 6 months balloons were fully biodegraded in
all but two patients.
Geometric analysis: The average prostate-rectum dis-
tance increased from 0.22 ± 0.2 cm before implant to
2.47 ± 0.47 cm after the implant. The average distance
reduced to 2.41 ± 0.43 cm at the end of radiotherapy
(statistically non significant). The balloon dimensions 7 days
post-implant and at the end of radiotherapy were as fol-
lows: width 3.06 ± 0.27 cm and 2.96 ± 0.25 cm (p = 0.03);
The implantable balloon
Figure 2 Sagittal view of CT scan, 7 days post balloon implant.
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1.86 ± 0.24 cm and 1.67 ± 0.22 cm, respectively. Sagittal
reconstruction was possible in only 18 of 23 patients. In
the remaining 5 patients the reconstruction failed due to
the CT scan slice thicknesses that ranged between 2.5 and
10 mm. The three dimensional parameters of the prostate
gland before the balloon implant, during radiotherapy
period, and at 3 months follow up, did not change signifi-
cantly (Table 4). Figures 1–2 present axial and sagittal CT
scan images demonstrating the location and configuration
of the implanted balloon.
Dosimetry analysis (Table 5): The comparison of the rec-
tal DVH histogram with and without the balloon implant
showed a significant decrease in all dosimetry parameters
for the rectum. Due to the small number of patients that
participated, no statistical significance could be expected
by evaluating differences in rectal DVH between 3D-CRT
and IMRT, and was therefore not compared. A DVH of
the PTV and rectum before and after the balloon implant
is shown in Figure 3.Table 5 Mean value of rectal dosimetry before and after
balloon implant
Pre implant Post implant Reduction % P-value
Mean value (Standard deviation)
V50 40% ± 17.8 25% ± 17.7 43 ± 28.3 P < 0.0001
V60 30% ± 17.4 15% ± 13.1 57 ± 28.4 P < 0.0001
D50 63Gy ± 20.2 48Gy ± 25.1 25 ± 28.2 P < 0.0001
D70 38Gy ± 16.1 22Gy ± 15.0 46 ± 26.2 P < 0.0001
D80 31Gy ± 15.2 15Gy ± 11.8 57 ± 25.9 P < 0.0001
D90 22Gy ± 14.3 8Gy ± 8.2 67 ± 25.6 P < 0.0001
D100 8Gy ± 8.3 1Gy ± 1.6 82 ± 22.1 P < 0.0001Discussion
Rectal toxicity remains a challenging issue in patients
receiving radiation therapy for prostate cancer, and as
mentioned in the introduction, two different methods have
been previously tested to address this problem. One is the
injection of a hydrogel spacer between the prostate and
rectum and the second is the use of an intra-rectal balloon.
The aim of this study was to evaluate the efficacy and
safety of a new biodegradable balloon transperineally
implanted into the rectal-prostate interspace. This inter-
national study is based on results from a small group of
27 patients. The implant procedure of the biodegradable
balloon was safely performed and was without significant
side effects in 26 patients (92%). There was no rectal injury
or bleeding. The most frequently reported side effect was
dysuria and 3 patients experienced transient acute urinary
retention which resolved following conservative treatment
and may have been triggered by the use of general anes-
thesia [21]. In three patients that underwent transrectal in-
sertion of a fiducial marker into the prostate prior to
the balloon implant, premature deflation of the balloon
occurred before the onset of radiation therapy. We hy-
pothesize that the fiducial markers, inserted through the
transrectal approach, remain in a vertical orientation and
thereby punctured the balloon resulting in its deflation. To
mitigate this problem, fiducial markers were inserted
transperineally in the remaining patients. In the remaining
23 patients the biodegradable implantable balloon achieved
a significant separation between prostate and rectum. The
mean prostate-rectum distance increased from 0.22 ±
0.2 cm to 2.47 ± 0.47 cm after the implant. This distance
remained without significant change during the entire
period of radiotherapy. The dimension of the implantable
balloon decreased slightly during the period of radiother-
apy but this change did not affect the prostate-rectum
Figure 3 DVHs pre and post balloon implant of a single patient: Continuous line pre and dashed line post balloon implant.
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implantable balloon to decrease the exposure of the rectum
to radiation during external beam radiotherapy for prostate
cancer. There was a significant reduction in rectal dose and
volume parameters. The follow-ups 3 and 6 months post-
implant demonstrated the complete deflation of the balloon
and its biodegradable property. Preliminary results were
presented at ASTRO 2010 and ESTRO 2011.
Our approach is similar in principle to the hydroluronic
acid injection concept. Though the materials differ, both
methods increase separation between the prostate and the
rectum. In both methods, significant and stable spacing
was achieved between the prostate and rectum during
entire period of radiation therapy. This resulted in a re-
duction of radiation exposure to the rectum during the
treatment of prostate cancer. Our study differs from the
intra-rectal balloon method. In our study, the entire rec-
tum is separated from the prostate. In the latter, the anter-
ior wall of the rectum remains proximal to the prostate,
and continues to be exposed to a higher dose of radiation.
Fixation using the intra-rectal balloon comes at the price
of daily insertion which is time-consuming and may be un-
comfortable for the patient. With further follow-up, the
community of radiation oncologists specializing in treating
prostate cancer along with prostate cancer patients will ef-
fectively judge which option is most viable.
Conclusion
Transperineal implantation of the biodegradable balloon
(ProSpace™) in patients undergoing prostate radiotherapyis safe and feasible. The balloon is stable and provides a
significant gap between prostate and rectal tissues.
A prospective phase II study is needed to confirm the
benefits of this implantable balloon on reducing rectal
toxicity during external beam radiotherapy of the
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